The Russian government extended on Thursday its approval for drugmaker Pharmasyntez to produce a generic version of U.S. anti-COVID-19 drug remdesivir without a patent for one year, citing the need to protect its citizens.
Pharmasyntez asked the Kremlin to allow it to produce a generic version of U.S. COVID-19 drug remdesivir in November 2020 without consent from U.S. company Gilead SciencesRussia's Supreme Court in May rejected a lawsuit from Gilead Sciences that challenged the decision to let Pharmasyntez develop and market remdesivir.The governmental decree published on Thursday said Pharmasyntez has to pay compensation to the drug's patent-holder, without specifying the amount.
Pharmasyntez produces remdesivir under the name Remdeform. A shipment of the drug was sent by Russia to India as part of a delivery of humanitarian aid.Reporting by Andrey Ostroukh; Editing by Toby ChopraSubscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Cook County COVID mandate: Chief judge requiring employees to get COVID-19 vaccineA new Cook County vaccination mandate is in effect. The chief judge is requiring his employees to get the COVID vaccine, citing surging omicron cases.
続きを読む »
COVID IL: Illinois Lt. Gov. Juliana Stratton tests positive for COVID-19Illinois Lt. Gov. Juliana Stratton announced Thursday she tested positive for COVID-19. She had received her COVID vaccine and booster.
続きを読む »
Russia confirms 103 Omicron cases of COVID-19Russia has now confirmed 103 cases of the Omicron variant of COVID-19, Anna Popova, the head of state consumer watchdog Rospotrebnadzor, said in an interview on state television on Thursday.
続きを読む »
Doc Rivers Enters NBA's COVID-19 ProtocolsBREAKING: Philadelphia 76ers coach Doc Rivers has entered the NBA’s COVID-19 health and safety protocols, source confirms to NBC Sports Philadelphia’s JClarkNBCS.
続きを読む »